""We aim to develop innovative, RNA-based therapeutics to address unmet medical needs for patients with genetic disorders.""
Prosensa, part of the BioMarin family, is focused on the discovery, development and commercialization of RNA-modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a focus on neuromuscular and neurodegenerative disorders, such as Duchenne Muscular Dystrophy, Myotonic Dystrophy and Huntington’s disease.
Prosensa was established in 2002 to develop novel treatments for life-threatening genetic disorders based on its RNA modulation platform. Prosensa intends to discover, develop and commercialize these products and to create a specialized orphan drug franchise.
Prosensa closely collaborates with key academic centers, patient advocacy groups, as well as corporate partners, in order to achieve its objective of bringing innovative treatments to patients as quickly as possible.
Phone: +31 (0) 71 33 22 100
Monday - Friday from 8.30 till 17.00